Nuvectis Pharma (NVCT) Enterprise Value (2022 - 2026)

Nuvectis Pharma has reported Enterprise Value for 6 years, with the latest figure at -$25.1 million in Q1 2026.

• Quarterly Enterprise Value rose 16.05% year-over-year to -$25.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$25.1 million (up 16.05% YoY) and the FY2025 annual result came in at -$31.6 million, down 70.69% from the prior year.
• Enterprise Value advanced to -$25.1 million in Q1 2026 per NVCT's latest filing, from -$31.6 million in the prior quarter.
• Over five years, Enterprise Value peaked at -$13.6 million in Q2 2022 and troughed at -$35.4 million in Q3 2025.
• A 5-year average of -$22.3 million and a median of -$20.8 million in 2023 frame the typical range for Enterprise Value.
• The sharpest annual moves came in 2024 and 2025: Enterprise Value advanced 26.36% in 2024, then sank 106.43% in 2025.
• Over 5 years, Enterprise Value stood at -$23.6 million in 2022, then advanced by 18.96% to -$19.1 million in 2023, then climbed by 3.1% to -$18.5 million in 2024, then tumbled by 70.69% to -$31.6 million in 2025, then gained by 20.65% to -$25.1 million in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered -$25.1 million, -$31.6 million, and -$35.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.